Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

NB-UVB phototherapy may restore adalimumab efficacy in chronic plaque psoriasis after treatment failure. Learn more about ...

Complete clearance lasts for a very long time due to knockout of resident memory T cells within the skin,’ said the study’s ...

Both drugs also showed in their phase 3 trials that they were superior to Amgen's oral PDE4 inhibitor Otezla (apremilast), ...

Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that ...

The XGBoost model predicts hyperglycemia risk in psoriasis patients with high accuracy, achieving an AUC of 0.821 in the training set. A web-based calculator was developed to facilitate personalized ...

The clinical-stage biotechnology company is seeking regulatory clearance to begin clinical trials of CYPS317, an allogeneic ...

In a recent review published in Signal Transduction and Targeted Therapy, researchers reviewed existing data on psoriasis etiopathogenesis and treatment. Psoriasis is a prevalent, chronic, ...

Psoriasis—a skin disease that can cause everything from red, itchy skin to a form of arthritis (psoriatic arthritis), and affects as many as 7 million Americans—is a chronic condition. But there are ...

Psoriasis causes your body to make new skin cells too quickly. These cells tend to pile up and form spots, bumps, and thick scaly patches called plaques that can be uncomfortable. Scientists think ...

Psoriasis is a lifelong condition that comes and goes in flares, and the key to managing it is the right treatment. Your dermatologist will help you find a therapy based on: How bad your symptoms are ...